Alpha 1 adrenergic blocking drugs such as prazosin can be used in the treatment of benign prostatic hyperplasia. They work by relaxing the smooth muscle of the bladder and prostate. Prescribers can now consider using alfuzosin as an alternative to prazosin, tamsulosin and terazosin in patients who have symptoms of benign prostatic hyperplasia.
early studies used 2.5 mg and 5 mg tablets, but the manufacturer is now marketing a 10 mg prolonged-release formulation. The tablet is taken daily after a meal as bioavailability is reduced if it is taken on an empty stomach. The half-life is about nine hours and only slightly increases with age.
Most of a dose is metabolised, then excreted in the faeces. As this metabolism involves cytochrome P450 3A4, alfuzosin may interact with inhibitors of this enzyme such as the imidazole antifungals. Hepatic insufficiency is a contraindication.
In the early 1990s, 5 mg sustained-release tablets were studied for three months in 390 men with symptomatic benign prostatic hyperplasia. A twice-daily dose significantly reduced symptom scores and the urine flow rate improved significantly more with alfuzosin than with placebo. The amount of residual urine was also significantly reduced. 1 A pooled analysis of three subsequent studies of a 10 mg sustained-release formulation reported results after 12 weeks of treatment. Compared with 482 men given placebo, the 473 who were randomised to receive alfuzosin had a significant improvement in lower urinary tract symptoms. The absolute decrease in the 35-point international prostate symptom score (IPSS) was 4.2 points with placebo and 6 points with alfuzosin.
There was also a significant improvement in the urinary peak flow rate. 2 In an open-label extension of one of these studies, 310 men took alfuzosin 10 mg for nine months. The improvements in the IPSS and urine flow were maintained. 3 Another one of the trials included 158 patients taking 0.4 mg tamsulosin, which is also an alpha 1 adrenergic blocker. After 12 weeks their IPSS had reduced by 6.5 points which was identical to the reduction seen in the 154 patients who were randomised to take alfuzosin 10 mg. These changes were significantly greater than the 4.6 point reduction seen in the 153 patients who took placebo. 4 When alfuzosin was compared with doxazosin in 210 men, both drugs significantly improved urinary flow rates over 14 weeks. The reduction in the IPSS was significantly greater with doxazosin (9.2 points) than with alfuzosin (7.5 points).
The residual volume of urine was also significantly less with doxazosin. However, this trial used the 2.5 mg and 5 mg formulations of alfuzosin and the mean dose was less than 10 mg, which is now the recommended dose. 5 Alfuzosin has also been studied as an adjunctive treatment in the management of acute urinary retention. Following catheterisation, 238 men were given daily alfuzosin and 122
were given a placebo. The catheters were removed after two doses and treatment continued for the day after removal. A return to satisfactory micturition was achieved by 61.9% of the alfuzosin group and 47.9% of the placebo group. A group of 165 responders was then randomised to take alfuzosin or a placebo for six months. During this period surgery for prostatic hyperplasia was needed by 17.1% of the alfuzosin group and 24.1% of the placebo group. Approximately 14 men would need to be treated for six months for one to avoid surgery. 6 As alpha 1 In the pooled analysis 9.5% of patients taking alfuzosin stopped treatment compared with 8.7% of the placebo group.
Symptoms associated with vasodilation occurred in 6.6% of elderly patients and 8.3% of those with hypertension. 2 In a meta-analysis alfuzosin caused significantly more dizziness, hypotension or syncope than placebo. 7 Alfuzosin has been available overseas for many years. No specific safety problems have emerged, but there could be a risk of the 'floppy iris syndrome', a complication in cataract surgery, which has been reported with similar drugs such as tamsulosin.
Although alfuzosin has some statistically significant effects, their clinical relevance is less clear. As the IPSS has to change by at least three points to be noticed, the benefit of alfuzosin over placebo is modest. In the pooled analysis, placebo increased the maximum urinary flow by 12.5%, while alfuzosin increased it by Some of the views expressed in the following notes on newly approved products should be regarded as tentative, as there may be limited published data and little experience in Australia of their safety or efficacy. However, the Editorial Executive Committee believes that comments made in good faith at an early stage may still be of value. As a result of fuller experience, initial comments may need to be modified. The Committee is prepared to do this. Before new drugs are prescribed, the Committee believes it is important that full information is obtained either from the manufacturer's approved product information, a drug information centre or some other appropriate source. The approval of clofarabine is based on a phase II study of 61 people whose acute lymphocytic leukaemia was refractory or had relapsed at least twice. Their ages ranged from 1 to 20 years with a median of 12 years. Clofarabine was infused for five consecutive days every 2-6 weeks for up to 12 cycles depending on the toxicity of the treatment. As judged by blood counts and bone marrow aspirates, 20% of patients had a complete remission and 10% had a partial remission. Some of these remissions were in patients whose leukaemia had been refractory to previous treatment. 1 Clofarabine is an antimetabolite so it frequently causes serious adverse effects. In the first two treatment cycles 72% of the patients had severe febrile neutropenia. Another meta-analysis looked at sleep disorders secondary to other conditions or sleep restriction, for example jet lag. It found no evidence that melatonin was of any benefit. 3 The meta-analysis of primary insomnia concluded that larger controlled trials were needed. 2 one subsequent trial in general practice randomised 170 patients, over the age of 55 years, with primary insomnia to take 2 mg modifiedrelease melatonin or placebo. After three weeks there was no significant difference in getting to sleep, but sleep quality and alertness the next day were significantly improved with melatonin. 4 A similar trial in general practice randomised 177 patients to take 2 mg modified-release melatonin and 177 to take a placebo. After three weeks, patients given melatonin fell asleep approximately nine minutes faster than the placebo group. They also had greater improvements in their quality of sleep and morning alertness, however total sleep time was not significantly improved. 5 Adverse events occurred in 37% of the patients given melatonin and 32% of the patients given placebo. The most frequently reported symptoms were headache, back pain, asthenia and pharyngitis.
New drugs
Melatonin undergoes significant first pass metabolism and most of the dose is excreted in the urine as metabolites. Nebivolol is indicated for the treatment of essential hypertension (no age limit), and for stable chronic heart failure in combination with conventional therapies for patients aged 70 or older. It works by blocking the beta 1 adrenergic receptor, and has mild vasodilatory properties mediated through nitric oxide release.
At doses up to 10 mg, it is selective for the beta 1 adrenergic
receptor, but at higher doses (and in poor metabolisers) it inhibits both beta 1 and beta 2 adrenergic receptors. In a meta-analysis of hypertension drugs, response rates to nebivolol (5 mg daily) were similar to other beta blockers, calcium channel antagonists and the angiotensin receptor antagonist losartan. Response rates to nebivolol were higher than for angiotensin converting enzyme inhibitors. 4 In one of the original hypertension trials that tested nebivolol (1.25-40 mg) for 12 weeks, headache (6-9%), fatigue (1.2-4.8%)
and dizziness (1-9%) were commonly reported adverse events.
Patients treated with the higher doses of nebivolol (20 mg and 40 mg) had significantly more adverse events, possibly because nebivolol becomes less selective at higher doses.
There were two serious adverse events that were thought to be possibly related to nebivolol (20 mg and 40 mg dose). Both were abnormal eCG readings which resolved spontaneously without treatment being interrupted. High-density lipoprotein cholesterol decreased significantly with increasing nebivolol dose, and increases in serum uric acid and phosphorus were observed at doses of 5 mg and above. 1 In the extension study, there were three patients with serious adverse events that were thought to be related to the study drug. These included right upper quadrant pain, bradycardia and peripheral oedema, and sexual dysfunction. obese patients (≥ 30 kg/m 2 ) tended to have more adverse events than patients who were not obese. 3 In the meta-analysis, adverse event rates for nebivolol were lower than for other beta blockers, calcium channel antagonists and losartan. The tolerability of nebivolol and ACe inhibitors was similar. 4 In Australia, nebivolol has also been approved as an add-on treatment for heart failure in older patients. This is based on the SeNIoRS trial in 2128 patients aged 70 years and over with heart failure. This was a post hoc analysis and patients were not randomised to receive different doses of nebivolol. They were started on placebo, or a low dose of nebivolol which was gradually increased to 10 mg, if tolerated, over a maximum of 16 weeks. The target dose was reached by two-thirds of the patients in the nebivolol group and was associated with a significant reduction (relative risk reduction of 4.2%) in the composite end point of all-cause mortality or hospitalisation (due to a cardiovascular event), compared to placebo. However, nebivolol did not significantly reduce all-cause mortality alone. There was no significant benefit with low-dose nebivolol and patients who could not tolerate it had a higher risk of death or hospitalisation than those on placebo. It is not clear how nebivolol compares to other beta blockers in this population. 5 In the heart failure trial, around 20% of patients had aggravated cardiac failure regardless of whether they were taking placebo or nebivolol. However, bradycardia was considerably more common with nebivolol than with placebo (11% vs 2.5% of patients). Dizziness was reported by 14% of patients in the nebivolol group and 13% in the placebo group. 5 Spontaneous adverse events reported overseas with this drug have included abnormal liver function, acute pulmonary oedema, acute renal failure, myocardial infarction, Raynaud's phenomenon, thrombocytopenia and skin disorders including rashes. However, their frequency and causal relationship with nebivolol is not known.
Nebivolol has the potential to interact with many drugs, therefore it is important to read the product information before prescribing it. Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, quinidine, thioridazine and cimetidine, are likely to increase nebivolol concentrations so patients' blood pressure should be monitored closely in case dose adjustment is required. As beta blockade can depress myocardial contractility, it can worsen heart failure so nebivolol should not be given to patients with acute heart failure or untreated congestive heart failure.
other contraindications include sick sinus syndrome (without pacemaker), severe bradycardia, heartblock (more than first degree), hypotension, severe circulatory disturbances, metabolic acidosis and history of bronchospasm.
As with other beta blockers, patients should be warned against stopping nebivolol abruptly as this can exacerbate angina and precipitate myocardial infarction and ventricular arrhythmias. Rizatriptan is a serotonergic agonist which mainly acts on 5HT 1B and 5HT 1D receptors. This constricts the extracerebral and intracranial arteries which become dilated during an attack of migraine.
The wafers have a bioavailability of 45%. Food may affect
absorption, but appears to have no effect on efficacy.
Rizatriptan is metabolised by monoamine oxidase so it should not be prescribed for patients who have taken monoamine oxidase inhibitors in the previous two weeks. Plasma An early dose-ranging study compared rizatriptan with sumatriptan and placebo. The study assessed 449 patients and found that headache was reduced within two hours in 18% of the placebo group, 46% of the sumatriptan group and 52%
of the patients who took 10 mg rizatriptan. This dose relieved pain completely in 26% of patients compared with 22% of the sumatriptan group and 3% of the placebo group. The headache returned in 41% of the patients taking rizatriptan 10 mg and 41%
of the sumatriptan group. 1 If the headache returns, patients can take another dose of rizatriptan, but doses must be at least two hours apart and not exceed 30 mg in 24 hours.
As rizatriptan has been marketed overseas for several years, there are many studies of its use in migraine, however only some of these studied the wafer formulation. Two hours after a dose, 66% of patients with moderate to severe headache will respond to a wafer and 47% will respond to a placebo.
A meta-analysis found more patients responded to a 10 mg dose of rizatriptan than to a 100 mg dose of sumatriptan. Significantly more were pain free after two hours, but the headache was more likely to return within 24 hours in patients taking rizatriptan. 2 The meta-analysis was used to calculate the number of patients who need to be treated for 100 to have sustained relief for 24 hours. These figures were 490 for sumatriptan 100 mg, and 458 for rizatriptan 10 mg. To treat 100 patients successfully Rizatriptan has also been compared with other analgesics for migraine. In one placebo-controlled study 200 patients were randomised to take rizatriptan tablets, paracetamol, or both.
After two hours 90% of the patients taking both drugs had responded compared with 77% of the rizatriptan group, 70%
of the paracetamol group and 46% of the placebo group. over 24 hours 62% of the patients taking both drugs had sustained relief, but this was not statistically superior to the 53% of the rizatriptan group and the 42% of the paracetamol group. 4 Adverse events occur at a similar frequency to reactions to sumatriptan 100 mg. 2 
